s
GORTEC Announces New Trial Success for Head and Neck Cancer Treatment
07-01-2025, 14:10
TOURS, France, Jan. 7, 2025 /PRNewswire/ — GORTEC, known as Head and Neck Radiation Oncology Group, today announced that the randomized Phase 3 NIVOPOSTOP GORTEC 2018-01 trial evaluating nivolumab, Bristol Myers Squibb’s anti-PD-1 therapy, as a post-operative treatment component for resected patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN), with high […] L'articolo GORTEC Announces New Trial Success for Head and Neck Cancer Treatment proviene da La Ragione.
CONTINUA A LEGGERE
17
0
0
Guarda anche
Libero Quotidiano
GORTEC Announces New Trial Success for Head and Neck Cancer Treatment
La Ragione
21:32
Dl sicurezza: Cdm, i punti del decreto
La Ragione
20:43
Ue, Della Valle “Riarmo è proposta insostenibile”
La Ragione
20:38
Difesa: Conte, ‘in piano riarmo non c’è difesa comune europea’
La Ragione
20:25